HC Wainwright & Co. Reiterates Buy on Day One Biopharmaceutical, Maintains $45 Price Target
HC Wainwright & Co. analyst Andres Maldonado reiterates Day One Biopharmaceutical (NASDAQ:DAWN) with a Buy and maintains $45 price target.
Capital One Initiates Coverage On Day One Biopharmaceutical with Overweight Rating, Announces Price Target of $40
Capital One analyst Naureen Quibria initiates coverage on Day One Biopharmaceutical (NASDAQ:DAWN) with a Overweight rating and announces Price Target of $40.
Where Day One Biopharmaceutical Stands With Analysts
Within the last quarter, Day One Biopharmaceutical (NASDAQ:DAWN) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent…
Oppenheimer Initiates Coverage On Day One Biopharmaceutical with Perform Rating
Oppenheimer analyst Matthew Biegler initiates coverage on Day One Biopharmaceutical (NASDAQ:DAWN) with a Perform rating.
Piper Sandler Maintains Overweight on Day One Biopharmaceutical, Raises Price Target to $45
Piper Sandler analyst Joseph Catanzaro maintains Day One Biopharmaceutical (NASDAQ:DAWN) with a Overweight and raises the price target from $40 to $45.
Day One Announced Sunday Topline Data from Pivotal Phase 2 FIREFLY-1 Trial Demonstrating Meaningful Responses with Tovorafenib (DAY101) in Recurrent or Progressive Pediatric Low-Grade Glioma
Day One Biopharmaceuticals (NASDAQ: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced positive topline results from the ongoing, open-label, pivotal Phase 2 FIREFLY-1 trial evaluating the invest
Needham Initiates Coverage On Day One Biopharmaceutical with Buy Rating, Announces Price Target of $40
Needham analyst Ami Fadia initiates coverage on Day One Biopharmaceutical (NASDAQ:DAWN) with a Buy rating and announces Price Target of $40.
Goldman Sachs Initiates Coverage On Day One Biopharmaceutical with Buy Rating, Announces Price Target of $45
Goldman Sachs analyst Andrea Tan initiates coverage on Day One Biopharmaceutical (NASDAQ:DAWN) with a Buy rating and announces Price Target of $45.
Benzinga’s Top Ratings Upgrades, Downgrades For December 1, 2022
Upgrades Northcoast Research upgraded the previous rating for SpartanNash Co (NASDAQ:SPTN) from Neutral to Buy. SpartanNash earned $0.55…
5 Value Stocks In The Healthcare Sector
What is a Value Stock?
A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.